A phase III skin cancer chemoprevention study of DFMO: Long-term follow-up of skin cancer events and toxicity

Cancer Prevention Research

Volumn 5, Issue 12, 2012, Pages 1368-1374

  Kreul, Sarah M ^a,b   Havighurst, Tom ^a   Kim, Kyung Mann ^a,b   Mendonça, Eneida A ^b   Wood, Gary S ^a,b   Snow, Stephen ^b   Borich, Abbey ^b   Verma, Ajit ^a,b   Bailey, Howard H ^a,b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BODY SURFACE; CANCER PREVENTION; CANCER RECURRENCE; CHEMOPROPHYLAXIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REBOUND; RETROSPECTIVE STUDY; SKIN CANCER; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION;

ADULT; AGED; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; DOUBLE-BLIND METHOD; EFLORNITHINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PLACEBOS; SKIN NEOPLASMS; WISCONSIN;

EID: 84870662091     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0233     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J, Ward E, Cancer Statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Thieden E, Philipsen PA, Sandby-Møller J, Wulf HC. Sunscreen use related to UV exposure, age, sex, and occupation based on personal dosimeter readings and sun-exposure behavior diaries. Arch Dermatol 2005;141:967-73. (Pubitemid 46165520)
3. Green A, Williams G, Neale R, Hart V, Leslie D, Parsons P, et al. Daily sunscreen application and beta carotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomized controlled trial. Lancet 1999;354:723-9. (Pubitemid 29405786)
4. Norval M, Lucas RM, Cullen AP, de Gruijl FR, Longstreth J, Takizawa Y, et al. The human health effects of ozone depletion and interactions with climate change. Photochem Photobiol Sci 2011;10:199-225.
5. Ulrich C, Kanitakis J, Stockfleth E, Euvrard S. Skin cancer in organ transplant recipients: where do we stand today? Am J Transplant 2008;8:2192-8
6. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010;146:283-7.
7. Ramsay HM, Reece SM, Fryer AA, Smith AG, Harden PN. Seven-year prospective study of nonmelanoma skin cancer incidence in U.K. renal transplant recipients. Transplantation 2007;84:437-9. (Pubitemid 47258336)
8. Bath-Hextall F, Leonardi-Bee J, Somchand N, Webster A, Delitt J, Perkins W. Interventions for the prevention of non-melanoma skin cancers in high-risk groups. Cochrane Database System Rev 2007:CD005414.
9. Birch-Johansen F, Jensen A, Mortensen L, Olesen AB, Kjær SK. Trends in the incidence of nonmelanoma skin cancer in Denmark 1978-2007: rapid incidence increase among young Danish women. Int J Cancer 2010;127:2190-8.
10. Christenson LJ, Borrowman TA, Vachon CM, Tollefson MM, Otley CC, Weaver AL, et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 2005;294:681-90. (Pubitemid 41159287)
11. Chen JG, Fleischer AB Jr, Smith ED, Kancler C, Goldman ND, Williford PM, et al. Cost of nonmelanoma skin cancer treatment in the United States. Dermatol Surg 2001;27:1035-8. (Pubitemid 34019722)
12. Housman TS, Feldman SR, Williford PM, Fleischer ABJr, Goldman ND, Acostamadiedo JM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003;48:425-9. (Pubitemid 36337080)
13. Wright TI, Spencer JM, Flowers FP. Chemoprevention of nonmelanoma skin cancer. J Am Acad Dermatol 2006;54:933-46.
14. Levine N, Moon TE, Cartmel B, Bangert JL, Rodney S, Dong Q, et al. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Cancer Epidemiol Biomarkers Prev 1997;6:957-61. (Pubitemid 27481645)
15. Frieling UM, Schaumberg DA, Kupper TS, Muntwyler J, Hennekens CH. A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the Physicians' Health Study. Arch Dermatol 2000;136:179-84. (Pubitemid 30090756)
16. Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs GF, et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 2003;95:1477-81. (Pubitemid 37279333)
17. O'Brien TG, Simsiman RC, Boutwell RK. Induction of the polyamine biosynthetic enzymes in mouse epidermis by tumor-promoting agents. Cancer Res 1975;35:1662-70.
18. Nowotarski SL, Origanti S, Shantz LM. Posttranscriptional regulation of ornithine decarboxylase. Methods Mol Biol 2011;720:279-92.
19. Haegele KD, Alken RG, Grove J, Schechter PJ, Koch-Weser J. Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase. Clin Pharmacol Ther 1981;30:210-7. (Pubitemid 12149141)
20. Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, et al. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2008;17:292-9. (Pubitemid 351272778)
21. Izbicka E, Streeper RT, Yeh IT, Pressley O, Grant M, Andrews JV, et al. Effects of alpha-difluoromethylornithine on markers of proliferation, invasion, and apoptosis in breast cancer. Anticancer Res 2010;30:2263-9.
22. Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008;1:9-11.
23. Bailey HH, Kim K, Verma AK, Sielaff K, Larson PO, Snow S, et al. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of a-difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev Res 2010;3:8-11.
24. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res 2010;3:696-706.
25. Klaassen I, Braakhuis BJ. Anticancer activity and mechanism of action of retinoids in oral and pharyngeal cancer. Oral Oncol 2002;38:532-42. (Pubitemid 34880115)
26. Sewell JL, Mahadevan U. Of blemishes and bowels: isotretinoin and inflammatory bowel disease. Gastroenterology 2010;138:392-4.
27. Oguri H, Hiruma T, Yamagishi Y, Oikawa H, Ishiyama A, Otoguro K, et al. Generation of anti-trypanosomal agents through concise synthesis and structural diversification of sesquiterpene analogues. J Am Chem Soc 2011;133:7096-105.
28. Pépin J, Khonde N, Maiso F, Doua F, Jaffar S, Ngampo S, et al. Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Bull WHO 2000;78:1284-95.
29. Barry DP, Asim M, Leiman DA, de Sablet T, Singh K, Casero RA Jr, et al. Difluoromethylornithine is a novel inhibitor of Helicobacter pylori growth, CagA translocation, and interleukin-8 induction. PLoS ONE 2011;6:e17510.
30. Huang C, Wang M, Zhang Y. Analysing panel count data with informative observation times. Biometrika 2006;93:763-76.
31. R. Core Development Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2011. ISBN 3-900051-07-0, Available from: www.R-project.org.
32. Elmets CA, Athar M. Targeting ornithine decarboxylase for the prevention of nonmelanoma skin cancer in humans. Cancer Prev Res 2010;3:8-11.